Search results
Results from the WOW.Com Content Network
This is defined by the World Health Organization (WHO) as a system "...to identify and prevent occurrence or recurrence of transfusion related unwanted events, to increase the safety, efficacy and efficiency of blood transfusion, covering all activities of the transfusion chain from donor to recipient."
In transfusion medicine, transfusion-associated circulatory overload (aka TACO) is a transfusion reaction (an adverse effect of blood transfusion) resulting in signs or symptoms of excess fluid in the circulatory system (hypervolemia) within 12 hours after transfusion. [2]
There are a series of guidelines and standards relevant to the laboratory released by the National Association of Testing Authorities, Australia (NATA), [2] Australian and New Zealand Society of Blood Transfusion (ANZSBT) [3] and RCPA. [4] Similarly, there are a series of clinical practice, patient blood management guidelines by the National ...
Transfusion dependence occurs when an average of more than 2 units of blood transfused every 28 days is required over a period of at least 3 months. [ 6 ] [ 7 ] Myelodysplastic syndromes is often only diagnosed when patients become anemic, and transfusion-dependent thalassemia is diagnosed based on gene mutations .
Patient Blood Management is an approach that can be implemented in hospital settings for taking care of people who require blood transfusions. [4] PBM includes techniques that may help ensure each person receiving a blood transfusion receives optimal treatment for their condition and also ensures that the blood supply (bank of donated blood) is maintained to ensure that all people who require ...
NHS Blood and Transplant is an executive special health authority of the United Kingdom's Department of Health and Social Care.It was established on 1 October 2005 to take over the responsibilities of two separate NHS agencies: UK Transplant (now renamed Organ Donation and Transplantation), founded by Dr. Geoffrey Tovey in 1972, [2] and the National Blood Service [3] (now renamed Blood Donation).
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation , where the engrafted lymphoid cells in the bone marrow are of donor origin (in autotransplant) and therefore ...
A review in people with blood cancers compared different platelet transfusion doses. [21] This review found no difference in the number of people who had clinically significant bleeding between platelet transfusions that contained a small number of platelets (low dose – 1.1 x 10 11 /m 2 ) and those that contained an intermediate number of ...